In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beta-O2 Technologies Ltd.

http://beta-o2.com

Latest From Beta-O2 Technologies Ltd.

Virtual Clinical Trials Find Bigger Voice As COVID-19 Forces Pharma Rethink

The use of virtual, real-time and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.

Innovation Clinical Trials

Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged

A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

Coronavirus COVID-19 BioPharmaceutical

Broncus Anticipates 2019 Completion Of EAST2 Study Of Archimedes Lung-Nodule Navigator

Results from a substudy of EAST2 focused on nodules without a bronchus sign or an airway leading to the nodule shows Broncus' Archimedes system, with proprietary virtual bronchoscopic navigation and "fused fluoroscopy" technology, provides access to nodules located anywhere in the lungs without puncturing the chest wall.

Clinical Trials Innovation

Market Intel: Micro-Invasive Glaucoma Implants Mark Hottest Growth Spot In Eye Surgery Products Market

The rising aging population and ever-increasing incidences of glaucoma and cataract are clearing a bright path for the ophthalmic surgical products market, which is expected to reach $9.4bn by 2021, a CAGR of 4.6% from 2016. Meddevicetracker expects that continued innovation in minimally invasive technologies and next-generation surgical systems, developed by giants like Alcon and smaller rivals, will address the need of hundreds of millions of people suffering from cataract and glaucoma, the two leading causes of blindness globally. In this feature, we'll take a closer look at the overall market and the key players in the individual segments of surgical systems, surgical instruments and IOLs. We'll take a deep dive into the smallest, yet fastest-growing MIGS devices segment and talk to surgeons about how they're transforming glaucoma management for their patients.

Ophthalmology Surgical Procedures
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Implantable Devices
UsernamePublicRestriction

Register